BRISBANE, Calif., Jan. 25 /PRNewswire-FirstCall/ -- InterMune, Inc. today announced that it will release fourth quarter and year-end 2004 financial results on Monday, February 7, 2005. The Company will host a live conference call and webcast at 8:30 a.m. EST that same day.
To access the live teleconference, dial 888-799-0528 (U.S.) or 706-634-0154 (international). To access the webcast, please log on to the Company’s website at http://www.intermune.com/ at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.
A replay of the webcast and teleconference will be available approximately three hours after the call for five business days. To access the replay, please call 800-642-1687 (U.S.) or 706-645-9291 (international), and enter the conference ID# 3686296.
About InterMune
InterMune is a biopharmaceutical company focused on developing and commercializing innovative therapies in hepatology and pulmonology. The Company has a broad and deep late-stage product portfolio addressing hepatitis C virus (HCV) infections, particularly nonresponders, or those patients who do not respond to first-line therapy, and idiopathic pulmonary fibrosis (IPF). Leading the hepatology portfolio is the DIRECT Trial, a Phase III study of daily Infergen(R) (interferon alfacon-1) plus ribavirin, and a Phase IIb trial of daily Infergen plus Actimmune(R) (interferon gamma-1b) with and without ribavirin for the treatment of HCV nonresponders. In addition, InterMune has an early stage small molecule program targeted at the HCV protease. The pulmonology portfolio includes pirfenidone and Actimmune. Pirfenidone is being developed for the treatment of IPF and for the treatment of Hermansky-Pudlak Syndrome. Actimmune is being investigated in the INSPIRE Trial, a Phase III study in patients with IPF. For additional information about InterMune and its development pipeline, please visit http://www.intermune.com/.
InterMune, Inc.
CONTACT: investors, Judy Hayes of InterMune, Inc., +1-415-466-2242, orir@intermune.com; or media, Carolyn Bumgardner Wang of WeissComm Partners,+1-415-692-4218, or carolyn@weisscomm.net, for InterMune, Inc.
Web site: http://www.intermune.com/